2hz4: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2hz4.jpg|left|200px]] | [[Image:2hz4.jpg|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_2hz4", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
--> | |||
{{STRUCTURE_2hz4| PDB=2hz4 | SCENE= }} | |||
}} | |||
'''Abl kinase domain unligated and in complex with tetrahydrostaurosporine''' | '''Abl kinase domain unligated and in complex with tetrahydrostaurosporine''' | ||
| Line 34: | Line 31: | ||
[[Category: Liebetanz, J.]] | [[Category: Liebetanz, J.]] | ||
[[Category: Manley, P.]] | [[Category: Manley, P.]] | ||
[[Category: | [[Category: Tyrosine kinase]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 06:53:18 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
Revision as of 06:53, 4 May 2008
Abl kinase domain unligated and in complex with tetrahydrostaurosporine
OverviewOverview
Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although most chronic phase CML patients treated with imatinib as first-line therapy maintain excellent durable responses, patients who have progressed to advanced-stage CML frequently fail to respond or lose their response to therapy owing to the emergence of drug-resistant mutants of the protein. More than 40 such point mutations have been observed in imatinib-resistant patients. The crystal structures of wild-type and mutant Abl kinase in complex with imatinib and other small-molecule Abl inhibitors were determined, with the aim of understanding the molecular basis of resistance and to aid in the design and optimization of inhibitors active against the resistance mutants. These results are presented in a way which illustrates the approaches used to generate multiple structures, the type of information that can be gained and the way that this information is used to support drug discovery.
DiseaseDisease
Known disease associated with this structure: Leukemia, Philadelphia chromosome-positive, resistant to imatinib OMIM:[189980]
About this StructureAbout this Structure
2HZ4 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia., Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW, Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006, Dec 13. PMID:17164530 Page seeded by OCA on Sun May 4 06:53:18 2008